Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Monotherapy for PCV: T&E vs Fixed Dosing
NCT03117634Phase 4Completed
- Sponsor
- Singapore National Eye Centre
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aflibercept in polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Singapore National Eye Centre. Primary endpoint: Mean Change in Best Corrected Visual Acuity at 52 weeks. Started Dec 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT03117634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117634.